Caris Life Sciences, Inc. Common Stock (CAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($44.78 Million) by net assets ($577.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Caris Life Sciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Caris Life Sciences, Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Caris Life Sciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andon Health Co Ltd
SHE:002432
|
0.023x |
|
Alkermes plc
F:8AK
|
0.093x |
|
Alfa S.A.B. de C.V.
MX:ALFAA
|
0.557x |
|
Taiwan Business Bank
TW:2834
|
-0.247x |
|
Victory Capital Holdings Inc
NASDAQ:VCTR
|
0.068x |
|
Chartwell Retirement Residences
TO:CSH-UN
|
0.045x |
|
Glarun Technology Co Ltd
SHG:600562
|
-0.001x |
|
E Ink Holdings
TWO:8069
|
0.059x |
Annual Cash Flow Conversion Efficiency for Caris Life Sciences, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Caris Life Sciences, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $577.31 Million | $83.16 Million | 0.144x | +46.79% |
| 2024-12-31 | $-2.50 Billion | $-245.20 Million | 0.098x | -23.77% |
| 2023-12-31 | $-2.14 Billion | $-276.10 Million | 0.129x | -23.31% |
| 2022-12-31 | $-1.70 Billion | $-285.71 Million | 0.168x | -57.45% |
| 2020-12-31 | $702.24 Million | $277.02 Million | 0.394x | +7.66% |
| 2019-12-31 | $693.24 Million | $254.00 Million | 0.366x | +42.90% |
| 2018-12-31 | $701.13 Million | $179.77 Million | 0.256x | -6.84% |
| 2017-12-31 | $563.85 Million | $155.19 Million | 0.275x | -2.58% |
| 2016-12-31 | $457.50 Million | $129.26 Million | 0.283x | -11.57% |
| 2015-12-31 | $461.26 Million | $147.37 Million | 0.319x | +1.30% |
| 2014-12-31 | $442.90 Million | $139.69 Million | 0.315x | +5.43% |
| 2013-12-31 | $415.13 Million | $124.19 Million | 0.299x | -2.87% |
| 2012-12-31 | $346.85 Million | $106.83 Million | 0.308x | +6.25% |
| 2011-12-31 | $248.74 Million | $72.11 Million | 0.290x | +35.07% |
| 2010-12-31 | $197.67 Million | $42.42 Million | 0.215x | -10.04% |
| 2009-12-31 | $129.10 Million | $30.80 Million | 0.239x | -1.06% |
| 2008-12-31 | $113.79 Million | $27.44 Million | 0.241x | +11988.54% |
| 2007-12-31 | $131.15 Million | $-266.00K | -0.002x | -100.67% |
| 2006-12-31 | $27.75 Million | $8.38 Million | 0.302x | -66.15% |
| 2005-12-31 | $32.99 Million | $29.41 Million | 0.891x | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more